Kezar Life Sciences Files 8-K
Ticker: KZR · Form: 8-K · Filed: Oct 4, 2024 · CIK: 1645666
| Field | Detail |
|---|---|
| Company | Kezar Life Sciences, INC. (KZR) |
| Form Type | 8-K |
| Filed Date | Oct 4, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, disclosure
Related Tickers: KZR
TL;DR
Kezar Life Sciences filed an 8-K, check for updates.
AI Summary
Kezar Life Sciences, Inc. filed an 8-K on October 4, 2024, reporting other events and financial statements. The filing does not contain specific details about the nature of these events or financial figures within the provided text.
Why It Matters
This filing indicates a material event or financial update for Kezar Life Sciences, Inc. that requires disclosure to investors.
Risk Assessment
Risk Level: low — The filing is a standard disclosure form without immediate negative or positive financial implications presented.
Key Players & Entities
- Kezar Life Sciences, Inc. (company) — Registrant
- 0000950170-24-112969 (filing_id) — Accession Number
- October 04, 2024 (date) — Date of Report
- 4000 Shoreline Court, Suite 300 (address) — Principal Executive Offices
- South San Francisco (location) — City of Principal Executive Offices
- California (location) — State of Principal Executive Offices
- 94080 (zip_code) — Zip Code of Principal Executive Offices
- 650-822-5600 (phone_number) — Registrant's Telephone Number
FAQ
What specific 'Other Events' are being reported by Kezar Life Sciences, Inc. in this 8-K filing?
The provided text of the 8-K filing does not specify the details of the 'Other Events' being reported.
Are there any financial statements or exhibits included with this 8-K filing, and what do they pertain to?
The filing indicates that 'Financial Statements and Exhibits' are included, but their specific content and purpose are not detailed in the provided text.
What is the Commission File Number for Kezar Life Sciences, Inc.?
The Commission File Number for Kezar Life Sciences, Inc. is 001-38542.
When was Kezar Life Sciences, Inc. incorporated, and in which jurisdiction?
Kezar Life Sciences, Inc. was incorporated in Delaware.
What is the principal business address of Kezar Life Sciences, Inc.?
The principal business address of Kezar Life Sciences, Inc. is 4000 Shoreline Court, Suite 300, South San Francisco, California, 94080.
Filing Stats: 429 words · 2 min read · ~1 pages · Grade level 10.4 · Accepted 2024-10-04 17:05:27
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value KZR The Nasdaq Stock Mark
Filing Documents
- kzr-20241004.htm (8-K) — 39KB
- kzr-ex99_1.htm (EX-99.1) — 12KB
- 0000950170-24-112969.txt ( ) — 161KB
- kzr-20241004.xsd (EX-101.SCH) — 23KB
- kzr-20241004_htm.xml (XML) — 4KB
01 Other Events
Item 8.01 Other Events. On October 4, 2024, Kezar Life Sciences, Inc. issued a press release providing an update on its zetomipzomib development program. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press release dated October 4, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. KEZAR LIFE SCIENCES, INC. Date: October 4, 2024 By: /s/ Marc L. Belsky Marc L. Belsky Chief Financial Officer and Secretary